System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Keiko Minashi, MD

Oncology — Chiba Cancer Center, Japan

LeadR Profile

Keiko Minashi, MD Chiba Cancer Center Japan
651 ScienceLeadR Reputation 651

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Surgery - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Chiba Cancer Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 206

Citations

Citations: 9 268 1st author: 10 Last author: 2 Unique author: 0

Main journals

J Clin Oncol 34
Gastrointest Endosc 26
Ann Oncol 24
Gastric Cancer 14
Esophagus 12

Best Journals

J Clin Oncol 23
Ann Oncol 14
N Engl J Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study.
incidence, neoplasms, stomach neoplasms, trastuzumab, ascites		J Gastric Cancer20260
Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.
cells, research design, esophageal diseases, carcinoma, squamous cell, carcinoembryonic antigen, chemoradiotherapy, esophageal squamous cell carcinoma		Dis Esophagus20260
Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.
safety, neoplasms, drug therapy, nivolumab, stomach neoplasms, chemotherapy		Gastric Cancer20260
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
progression-free survival, neoplasms, adenocarcinoma, drug therapy, drug-related side effects and adverse reactions, therapeutics, trastuzumab, chemotherapy		N Engl J Med Top journal20260
Nationwide quality indicator survey on the current practice of esophageal cancer management in Japan: report from the guideline committee for the 6th edition of the Japanese Esophageal Cancer Practice Guidelines.
neoplasms, drug therapy, endoscopy, therapeutics, esophageal neoplasms, alcohol abstinence, chemotherapy		Esophagus20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
Phase 2 2
N/A 1
Phase 2/Phase 3 1

By status:

Completed 4
Active not recruiting 1
Recruiting 1
Unknown 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Perioperative HLX10 (Serplulimab) With S 1 Oxaliplatin (SOX) in Locally Advanced and PD L1 Positive Gastric or Esophagogastric Junction Adenocarcinoma
NCT07699939 — tegafur, esophagogastric junction, adenocarcinoma, drug therapy, oxaliplatin, therapeutics, oxonic acid, chemotherapy		Phase 2Recruiting2026
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2 positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147 — cells, lewy bodies, stomach, parkinson disease, esophagus, neoplasms, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, immunotherapy, receptors, death domain, esophageal neoplasms, capecitabine, cell death, stomach neoplasms, trastuzumab, chemotherapy		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS